Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Collplant Holdings ( (CLGN) ) is now available.
On May 28, 2025, CollPlant Biotechnologies announced its first-quarter financial results and provided a corporate update, highlighting a $2 million milestone payment from AbbVie for their dermal filler collaboration. The company is advancing its regenerative breast implant program, which shows promising preclinical results, and is preparing its photocurable dermal filler for clinical trials. CollPlant’s efforts in expanding its international distribution network for Vergenix™ STR and securing patents for its rhCollagen bioinks underscore its strategic focus on innovation and market expansion.
The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
CollPlant Holdings’ overall stock score reflects its current financial struggles, characterized by a drastic revenue decline and increased losses. Despite some positive developments in its preclinical programs and collaborations, the company’s financial instability and weak technical indicators weigh heavily on its stock performance.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetics medicine company based in Israel, focusing on developing innovative technologies and products using its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics.
Average Trading Volume: 11,125
Technical Sentiment Signal: Sell
Current Market Cap: $22.11M
See more insights into CLGN stock on TipRanks’ Stock Analysis page.